Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Immunitybio Inc

IBRX ✓ COMPLIANT ☆ Track — members

Nasdaq · Healthcare · Biotechnology & Medical Research ·

USA Mid Cap Analyst: STRONG BUY

Last Close

$7.57

▼ -1.05%

Market Cap $8.02B · Vol 1.22M

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$8.02B

Mid Cap

Div Yield

N/A

EPS Growth

-150.00%

YoY

RSI (14)

61.42

Momentum

Beta

0.13

vs Market

52W High

$12.41

39.00% below

52W Low

$1.95

288.21% above

Volume

1.22M

Avg 2.21M

P/B

N/A

Price-to-book

ROE

N/A

Return on equity

Free Float

37.84%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Immunitybio Inc (IBRX) stock is Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does IBRX pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

-0.92%

-3.93%

-7.12%

+27.33%

YTD

+282.32%

+179.34%

+286.22%

-32.71%

Financials & Valuation

TTM · Annual

Total Revenue	$113.29M
Net Income	$-351,472,000.00
Revenue Growth (YoY)	+93.91%
Gross Margin	99.34%
Operating Margin	-226.00%
Net Profit Margin	-310.25%
ROE	N/A
ROA · ROIC	-79.47% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	16.08
P/B	N/A
P/FCF	N/A
EPS Growth	-150.00%
Outstanding Shares	1.06B

Technical Indicators

50-Day SMA	$7.65
200-Day SMA	$6.16
RSI (14)	61.42
Beta	0.13
52-Week High	$12.41
52-Week Low	$1.95

Volume Today	1.22M
Avg Daily Volume (30D)	2.21M
Relative Volume	0.55x
Volatility (10D)	36.79
Volatility (30D)	59.23
Free Float	37.84%

Analyst Consensus

STRONG BUY

Current Price $7.57

Mean Target $12.75

52W Low$1.95 52W High$12.41

Current

Target

$1.95 $12.41

Current Analyst target

+68.43% upside potential · 4 analysts

Identifiers

ExchangeNasdaq

FIGIBBG007T9DYX8

ISINUS45256X1037

CountryUnited States of America

Sub-IndustryBio Therapeutic Drugs

Earnings DateNov 2, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

2359.HK WuXi AppTec Co Ltd -2.85% ARGX.BR argenx SE -3.21% ARGX argenx SE -0.66% INSM Insmed Inc -2.05% 2269.HK WuXi Biologics (Cayman) Inc -1.27%

Company Profile

Immunitybio, Inc. is a vertically integrated, clinical-stage biotechnology company developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Using its applied science and platforms to treat cancers, including the development of potential cancer vaccines, as well as developing immunotherapies and cell therapies to reduce or eliminate the need for standard high-dose chemotherapy. Its platforms and their associated product candidates are designed to attack cancer and infectious pathogens by activating both the innate immune system, including NK cells, dendritic cells, and macrophages, as well as the adaptive immune system comprising B and T cells, in an orchestrated manner. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins, vaccine vectors, and cell therapies. Its biologic commercial product candidate, Anktiva, is an IL-15 superagonist antibody-cytokine fusion protein.